Sandeep Gupta, MD
Clinical Cardiac Electrophysiology · Middletown, OHNPI 1720055379
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.9%), food and beverage and other — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Boston Scientific at 40.1% of the total.
Across 356 payments — averaging $128.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$18K
- Medtronic$12K
- Abbott$11K
- Lantheus Medical Imaging, Inc.$840
- ZOLL Respicardia, Inc.$668
- Novartis$489
- plus $3K from 20 others
Across 35 payments — averaging $175.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$6K
What the payments were for
- Travel & lodging$24,72154%
- Food & beverage$20,25844%
- Education$220%
- Other$8402%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 135 | $18,390 |
| Medtronic(2 entities) | 105 | $11,647 |
| Abbott | 72 | $11,011 |
| Lantheus Medical Imaging, Inc. | 1 | $840 |
| ZOLL Respicardia, Inc. | 2 | $668 |
| Novartis | 4 | $489 |
| Atricure, Inc. | 2 | $377 |
| Kestra Medical Technology Services, Inc. | 5 | $354 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $306 |
| Impulse Dynamics (USA) Inc. | 3 | $291 |
| E.r. Squibb & Sons, L.L.C. | 2 | $250 |
| AstraZeneca | 3 | $215 |
| Johnson & Johnson | 3 | $191 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $104 |
| Amgen | 1 | $90 |
| Biotronik Inc. | 1 | $80 |
| Pfizer | 1 | $78 |
| Cardiva Medical, Inc. | 1 | $73 |
| Cardiofocus, Inc. | 1 | $70 |
| Sanofi-aventis U.S. LLC | 1 | $62 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Philips North America LLC | 1 | $37 |
| Boehringer Ingelheim | 1 | $23 |
| Merck | 1 | $19 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE$4,298
- ENSITE PRECISION$3,489
- Farapulse$3,173
- Arctic Front$2,854
- Rhythmia Mapping System$1,993
- DiamondTemp$1,362
- Micra$883
- Definity$840
- GENERAL - THERAPIES$807
- remede System$668
- AGILIS$608
- EMBLEM$542
- ENTRESTO$489
- EnSite Precision Cardiac Mapping System$484
- WATCHMAN Access System$461
- CARDIOBLATE CRYOFLEX$443
- Ensite Cardiac Mapping System$385
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$377
- ARCTIC FRONT ADVANCE$345
- CARDIOMEMS$268
How this compares
$45,841 in reported general payments places this provider in the 80th percentile of 159 clinical cardiac electrophysiology providers in Ohio.
See all clinical cardiac electrophysiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 294 | $331,874 |
| XareltoRivaroxaban | 72 | $72,717 |
| EntrestoSacubitril/Valsartan | 56 | $62,867 |
| JardianceEmpagliflozin | 11 | $15,303 |
| FarxigaDapagliflozin Propanediol | 19 | $13,747 |
| Propafenone Hcl | 97 | $5,282 |
| SotalolSotalol Hcl | 220 | $3,968 |
| Metoprolol Succinate | 331 | $3,555 |
| Amiodarone Hcl | 113 | $3,342 |
| Flecainide Acetate | 85 | $3,118 |
| Dofetilide | 14 | $2,903 |
| Valsartan | 119 | $2,492 |
| Rosuvastatin Calcium | 75 | $2,418 |
| Atorvastatin Calcium | 230 | $2,241 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 57 | $2,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $78 | $331,874294 claims |
| Johnson & JohnsonXarelto | $191 | $72,71772 claims |
| NovartisEntresto | $489 | $62,86756 claims |
| Boehringer IngelheimJardiance | $23 | $15,30311 claims |
| AstraZenecaFarxiga | $215 | $13,74719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 159 clinical cardiac electrophysiology providers in Ohio.
Other clinical cardiac electrophysiology in Middletown
- Anish AminColumbus$1.1M
- Walid SalibaCleveland$511K
- Mohamed KanjBeachwood$442K
- John HummelColumbus$275K
- Bruce WilkoffCleveland$213K
- Alexandru CosteaCincinnati$188K
- Auroa BadinColumbus$188K
- Gaurang GandhiCincinnati$179K
- Ralph AugostiniColumbus$174K
- Dina SparanoMayfield Heights$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.